Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer.
Yuan K, Li Z, Kuang W, Wang X, Ji M, Chen W, Ding J, Li J, Min W, Sun C, Ye X, Lu M, Wang L, Ge H, Jiang Y, Hao H, Xiao Y, Yang P.
Yuan K, et al. Among authors: ji m.
Nat Commun. 2022 May 25;13(1):2903. doi: 10.1038/s41467-022-30581-4.
Nat Commun. 2022.
PMID: 35614066
Free PMC article.